Teva rival Biogen reports success in oral MS trial – Globes
 Proactive Investors USA & Canada |
Teva rival Biogen reports success in oral MS trial
Globes Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) rival Biogen Idec Inc. (Nasdaq: BIIB) reported success in the Define Phase III clinical trial of its oral multiple sclerosis drug BG-12, a competitor's of Teva's Laquinimod. … Biogen Idec reports positive phase 3 data from MS drug Biogen oral MS drug candidate nears finish line JPMorgan Chase & Co. (JPM) Analysts Reiterate a "Neutral" Rating on Biogen … |
